ʻO ka hōʻike COVID-19 diagnostic variant test mua loa o ka honua, hiki ke kānana iā COVID-19 a me ka ʻike ʻana i nā ʻano mutant he nui i hoʻokahi hopena i hoʻomohala ʻia e kahi hui biotechnology Kōlea Hema.
ʻO kā Seegene hōʻike hōʻoia hou, ka 'Allplex ™ SARS-CoV-2 Variants I Assay,' hiki ke ʻike a hoʻokaʻawale i nā ʻano virus, me nā mea i ʻike ʻia he ʻoi aku ka make a me ka make.
ʻAʻole ʻike ka hōʻike loli hou i ka COVID-19, akā hiki ke ʻike pū kekahi i nā loli ʻano nui i manaʻo ʻia mai UK mai, ʻApelika Hema a me nā wahi ʻē aʻe e pili pū me Iapana a me Brazil.
Eia kekahi, hiki iā ia ke hōʻike mua i kahi ʻano laha hou, e hāʻawi ana i ka ʻike i nā ʻano hou aʻe, a he hiʻohiʻona nui nō hoʻi o ka ʻenehana Seegene.
Hoʻohui ka huahana hou a Seegene ma ka liʻiliʻi he ʻumi o kona mau ʻenehana ponoʻī, me ke ʻano multiplex manawa maoli PCR hana o mTOCE ™, ʻo ia ka ʻenehana hōʻoki e hiki wale iā Seegene ke hoʻohana. Hāʻawi kēia ʻenehana hōʻano hou i ka hoʻāʻo e ʻike i kahi kiko kikoʻī kikoʻī kahi i loaʻa ai ka hoʻololi ʻana, e hiki ai i ka ʻike kikoʻī a me ka hoʻokaʻawale ʻana o ka coronavirus a me nā mana i hoʻololi ʻia me kahi pū hoʻokahi reagent.
ʻO kekahi hiʻohiʻona ʻē aʻe e hoʻohana ana i ka ʻenehana ʻokoʻa ʻo Seegene ʻo ia ka endogenous control i loko e hiki ai ke hōʻoia i ke kaʻina hoʻokolohua holoʻokoʻa me ka hōʻiliʻili hāpana kūpono.
Ma ka hoʻohana ʻana i ka nānā nui auto data a Seegene i ka silika ʻōnaehana, ke nānā pono nei ka ʻoihana a me ke kālailai ʻana i ka waihona ma ka honua holoʻokoʻa ma COVID-19 a me nā ʻano like ʻole, e ʻae nei e pane koke me ka hoʻomohala huahana.
I kēia manawa ua koi ʻia nā aupuni a me nā luna olakino a puni ka honua e hilinaʻi i nā kaʻina hōʻike ʻokoʻa, ʻaʻole kūpono i ka hoʻāʻo nui ʻana, e kānana i nā ʻano virus mai nā hihia maikaʻi COVID-19. Ua ʻōlelo ʻia e kahi luna mai Seegene ʻo kāna "COVID-19 diagnostic variant test" e hoʻoliʻiliʻi nui i ka hiki ke hoʻāʻo nui i ka hakakā ʻana me ka hoʻolaha ākea ākea o nā virus i ka wā he kī no ka kaohi ʻana i ka maʻi ahulau. "
Hilinaʻi nā diagnostics o kēia manawa i ka hoʻāʻo PCR a i ʻole ka hoʻowalewale antigen / hoʻāʻo antibody e ʻike pono i ka maʻi COVID-19 a i ʻole ke ola ʻana o nā mea ʻohā. Akā ʻo nā ʻano hana diagnostic i kēia manawa he mau palena i ka nānā ʻana i nā ʻano mea hoʻomaʻi, ke kau nei i nā paleki i ka pale ʻana i ka maʻi ahulau. Hiki i ka hana PCR ke pale a ʻike i nā ʻano like ʻole, akā ʻaʻole i hiki i ka hana ʻana i kēlā me kēia kōmike reagent a hiki i ka hoʻāʻo ʻokoʻa hou ʻana a Seegene.
Wahi a ka luna o ka ʻoihana, Hoʻolālā ʻo Seegene "e hoʻolako i kāna hōʻike COVID-19 i nā hui ākea a me nā aupuni e like me kāna mea nui."
Ua ʻōlelo hou ka luna e hoʻomau ka hana a ka ʻoihana e "hoʻokō i ka hana ma ke ʻano he alakaʻi diagnostics molekino ākea ma o ka hana pū ʻana me nā luna olakino o ka honua."
He aha e lawe ʻia mai kēia ʻatikala:
- An official from Seegene said its “new COVID-19 diagnostic variant test will significantly boost massive testing ability in its fight against the global-spread of mutant viruses when the time is key to controlling the pandemic.
- This innovative technology allows the test to detect a target specific spot where mutation occurs, enabling precise detection and differentiation of the coronavirus as well as its mutated versions with a single tube of reagent.
- The official added that the company will continue its work to “fulfill the duty as a leading global molecular diagnostics company by closely working with health authorities around the world.
